Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FCER2 | P06734 | 5/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409719 | 0.99 | F7 (0.51) | F7MMP1ALDH1A1MAPTFCER2 | |
| SCHEMBL6411246 | 0.87 | MMP1 (0.54) | F7MMP1ALDH1A1MAPTCTSB | |
| SCHEMBL6407708 | 0.86 | MMP1 (0.53) | F7MMP1ALDH1A1MAPTCTSB | |
| SCHEMBL5494080 | 0.82 | TACR2 (0.55) | MMP1CTSBTACR2 | |
| SCHEMBL5160205 | 0.81 | F7 (0.59) | F7MMP1ALDH1A1FCER2CTSB | |
| SCHEMBL5492268 | 0.81 | TACR2 (0.57) | MMP1ALDH1A1TACR2 | |
| SCHEMBL6407136 | 0.80 | F7 (0.64) | F7MMP1ALDH1A1FCER2KMT2A | |
| SCHEMBL6411176 | 0.80 | F7 (0.57) | F7MMP1ALDH1A1FCER2KMT2A | |
| SCHEMBL5494652 | 0.79 | TACR2 (0.53) | ALDH1A1MAPTTACR2 | |
| SCHEMBL5491193 | 0.79 | TACR2 (0.55) | MMP1ALDH1A1MAPTTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | AVANIR PHARMACEUTICALS | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277690-A1 | Small molecules for treatment of hypercholesterolemia and related diseases | LDLR, NPC1L1, CETP | F7 4389/4885MMP1 3976/4885ALDH1A1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.